Histone deacetylase inhibitors: Anticancer compounds
Authors:
- Jerry L. WorkmanJWJerry L. Workman
- 1 January 2009
- journal article
- research article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 41 (1) , 21-25
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiationProceedings of the National Academy of Sciences, 2008
- Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic ProteinsMolecular Medicine, 2008
- Histone deacetylase inhibitors selectively suppress expression of HDAC7Molecular Cancer Therapeutics, 2007
- Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector designOncogene, 2007
- Acetylation and deacetylation of non-histone proteinsGene, 2005
- Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell LinesClinical Cancer Research, 2004
- Role of Class I and Class II histone deacetylases in carcinoma cells using siRNABiochemical and Biophysical Research Communications, 2003
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsThe EMBO Journal, 2001
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999
- Role of histone deacetylases in acute leukemiaJournal of Cellular Biochemistry, 1998